Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Highly encouraging preclinical data highlight the
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants Clinical estimates for SP-B deficiency have an incidence of 1 in 1 million live
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene
Executive Chair, David Hipkiss, will be attending JPM 2025 week in San Francisco week beginning 13th January 2025.
He will be meeting with investors and partners and also presenting an overview of AlveoGene and its innovative technology and pipeline at RESI JPM 2025 which takes place in person on January 14 at the Marriott Marquis San Francisco (780 Mission St, San Francisco, CA 94103).
Please reach out to request a meeting at [email protected]
Executive Chair, David Hipkiss, will be presenting as a Finalist in the Innovators Pitch Challenge at the RESI London Conference on 4th December 2024 at 11 Cavendish Square, London, UK. He will be meeting with a range of investors and potential partners. Please reach out to schedule a meeting and discuss AlveoGene’s innovative technology and pipeline at [email protected]
Executive Chair, David Hipkiss, will be attending Jefferies Conference at The Waldorf Hotel, London, UK from 19-21st November. He will be meeting with a range of investors and partners. Please reach out to schedule a meeting and discuss AlveoGene’s innovative technology and pipeline at [email protected]
Executive Chair, David Hipkiss, will present an overview of AlveoGene and its innovative technology and pipeline at the Inv€$tival Showcase on Monday 19 November at 15.00 hrs GMT at the Tobacco Dock in London, UK.
AlveoGene is working in partnership with the Oxford-Harrington Rare Disease Centre this week at the 2024 Oxford Harrington Rare Disease Symposium, which is taking place at Trinity College Oxford from 24-26 September.
David Hipkiss, Executive Chair be presenting AlveoGene‘s outstanding year of progress as we continue on our mission to transform rare respiratory disease outcomes using inhaled gene therapy.
AlveoGene’s InGenuiTy® platform uniquely combines efficacy, durability and convenience with potential lifelong protection from a single dose.
The Company will provide updates on our pipeline progress and latest developments in neonatal surfactant protein deficiencies (Lethal SP-B and ABCA3), Alpha-1 anti-trypsin deficency (AATD), and IPF.
AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.
AlveoGene’s Executive Chair David Hipkiss will be will be presenting the latest developments of the Company at 15.00hrs CET on Monday 13th May 2024, Rooms 4&5 ‘Cell & Gene Therapy Track’
Our InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest.
We have shown single dose efficacy, long-term durability of effect (critically retaining an ability to re-dose if required), combined with the convenience of administration, transforming the current standard of care of frequent IV bolus injections, or providing therapeutic solutions for diseases that currently do not exist.
For more information and to arrange a meeting, please contact us on [email protected]
